

**REMARKS**

Claims 1, 6-33 and 35-122 are pending in this application. Claims 7-14, 17-33 and 36-122 are withdrawn from consideration. Claims 1, 6, 15, 16 and 35 stand rejected and Applicant traverses these rejections.

Claims 1, 6, 15, and 35 are rejected under 35 U.S.C. § 112, 1<sup>st</sup> paragraph by the Examiner “because the specification does not provide a sufficient enabling description of a method of inducing secretion of interleukin-1 $\beta$  (IL-1 $\beta$ ) in *any* mammalian or human cell.”

Claims 15 and 16 are rejected under 35 U.S.C. 112 1<sup>st</sup> paragraph by the Examiner because “the claims contain subject matter not described in the specification. The specification does not provide support for “killing” cancer cells.”

Claim 16 is objected to as being dependent upon a rejected claim, and would be allowable if rewritten in independent form including all of the limitations of base claim and any intervening claims.

Applicant has cancelled Claims 1, 6, 15 and 35 and reserves the rights to refile these claims in a subsequently filed application. In an attempt to accelerate the prosecution of this Application, Applicant has amended Claim 16 to rewrite the claim as independent form including all the limitations of base claim and any intervening claims, as well as amended the claim to change the claim from “capable of killing of cancer cells” to “leading to apoptosis of the carcinoma cell.” Applicant has also added a new dependent Claim 123 to recite the antibody is a monoclonal antibody or polyclonal antibody.

Thus, Applicant submits the claims as amended are in condition for allowance and respectfully request an early notice of the same.

Respectfully submitted,

EVEREST INTELLECTUAL PROPERTY LAW GROUP

Date: June 23, 2006

BY

  
Tin-Chuen Yeung, Reg. No. 40,240  
P.O. Box 708  
Northbrook, IL 60065  
Phone: (847) 272-3400